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Special Feature 
The Clinicians' Guide to Creutzfeldt-Jakob Disease 
Thomas H. Swanson, MD* 
Creutzfeldt-Jakob disease, a transmissible, rapidly progressive dementia of unknown etiology, mimics 
Alzheimer's disease, presents in middle life, and affects many central nervous system structures. The 
disease progresses in three distinct stages, culminating in death. Its occurrence is sporadic and its 
distribution worldwide. Pathological changes are varied, but spongy degeneration ofthe neuropil is 
classic. Research on scrapie, the anirrml model of Creutzfeldt-Jakob disease, has demonstrated that 
this unconventional, slow disease is transmitted via a small (less than 50,000 mW) particle, which is 
composed principally of protein. How this infectious particle, variably rmmed prion, virino, or slow 
virus, invokes disease or is transmitted is unclear The agent does not evoke a host immune response, 
nor does it appear to contain nucleic acid. No treatment has proven successful, although amantadine 
has been partially effective in some cases. Decreased brain concentrations of dopamine and 
norepinephrine are associated pharmacological abnormalities. (Henry Ford Hosp Med J 
1987:35:76-83) 
Creutzfeldt-Jakob disease (CJD), a sporadic, dementing, transmissible illness, is tmly "one in a million," not only in 
its incidence but in its novel etiology as well. In the past, clini-
cians have had little exposure to this disease, but with recent rec-
ognition of human growth hormone-related CJD and advances 
in understanding the etiology of scrapie, a related animal dis-
ease, CJD has gained notoriety. While many excellent reviews 
discuss various aspects of CJD, a concise clinical guide to the 
affliction is conspicuously lacking in the literature. It is my in-
tention to provide a review of reasonable brevity, encompassing 
the areas of CJD research of most interest and practical value to 
the clinician. For this reason, every available paper in the liter-
ature is not reviewed. Instead, I have reviewed works that repre-
sent current, state-of-the-art developments important in our 
understanding this disease and those that detail historical devel-
opments, which serve to highlight the exciting evolution of en-
lightenment in this area. 
In 1920 Creutzfeldt described a progressive neurological dis-
order with dementia so similar to Alzheimer's disease that at one 
point it was named Alzheimer's type II disease (1,2). One year 
later, Jakob described four patients with similar signs and symp-
toms (3). Although these first cases were probably not tme cases 
of CJD as we know it, Creutzfeldt and Jakob are still honored by 
the eponymic designation (4). Since then, hundreds of reports of 
the same disorder have appeared in the literature, with names 
such as spastic pseudosclerosis, corticopallidospinal degenera-
tion, corticostriatalspinal degeneration, subacute spongiform 
encephalopathy, and Heidenhain's disease (5). The confusing 
nomenclature of this disease reflects our misunderstanding of 
what may be the most exciting group of diseases of the decade. 
CJD is grouped with other slow viral diseases of the nervous sys-
tem which are caused by an unconventional infectious agent and 
cause progressive, noninflammatory, spongiform encephalopa-
thies in animals and man. The characteristics that classify these 
diseases as "slow," a term coined by Sigurdsson in 1954 (6), 
are: 1) a long incubation period between exposure to the infec-
tious agent and manifestations of the disease, usually months to 
years; 2) a progressive clinical course typically fatal in weeks to 
months; and 3) localization of the disease to one organ system 
(7). 
Three other diseases are coclassified as unconventional, slow 
diseases: I) scrapie, affecting sheep and goats; 2) kum, affecting 
humans (8); and 3) transmissible mink encephalopathy. Much of 
what is known about the CJD infectious agent has been gleaned 
from research on these other infectious agents, particularly 
scrapie. Therefore, references will be made to the scrapie agent 
periodically throughout this paper 
Diagnosis 
CJD presents late in middle life as a progressive central ner-
vous system disease (9). Often the disease presents insidiously 
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with vague symptoms of confusion, depression, insomnia, 
peculiar sensations, and visual complaints (9). A progressive 
dementia develops within weeks to months, with clinical signs 
and symptoms of cerebellar, basal ganglial, focal motor, pyra-
midal, and lower motor neuron involvement (9,10). Although 
myoclonus is a common late occunence, it may appear at any 
stage ofthe disease (9). In addition, seizures develop occasion-
ally (9), Patients then progress to an akinetic state and typically 
die within one year (9,10). Sleep apnea has been reported in 
several cases, but is not a consistent finding (11). Electroen-
cephalographic changes initially include attenuation of back-
ground activity and appearance of nonspecific dysrhythmic 
changes (9,10,12,13), This activity progressively evolves to gen-
eralized slow-wave activity associated with variable degrees of 
bilaterally diffuse synchronous discharges (9,10,12,13). Al-
though some authors disagree, periodic lateralized epileptiform 
discharges (PLEDs) may be an eariy electroencephalographic 
manifestation (14). Brain stem auditory- and visual-evoked as 
well as somatosensory-evoked potentials are all normal (15). 
Spinal fiuid in CJD is reported to be normal by most authors 
(9,10,12,13), although some patients have shown a mild increase 
in cell count and/or protein (9), and increased IgG protein with 
oligoclonal bands has been reported in both the "typical" and 
"ataxic" forms (15,16). Computerized tomographic scanning 
and magnetic resonance imaging reveal no abnormalities except 
mild cerebral atrophy in some cases (17). 
Bernoulli et al (18) reviewed the early clinical features of CJD 
in 100 cases and suggested that three stages of the disease exist 
as originally proposed by Jansen and Monrad-Krohn (19). Dur-
ing stage I the patient becomes aware of some physical or mental 
disorder, with minor sensorimotor or behavioral changes, which 
are initially insufficient to interfere with daily life. Stage II 
heralds signs of definite neurologic dysfunction with some 
alteration in the patient's day-to-day activities. Stage III is char-
acterized by incapacitating dementia, usually with severe 
myoclonus. 
Included in the differential diagnosis of CJD are Alzheimer's 
disease. Pick's disease, normal pressure hydrocephalus, 
Parkinson's disease, Huntington's disease, amyotrophic lateral 
sclerosis, progressive supranuclear palsy, multiple sclerosis, 
intracranial mass lesions, cerebrovascular disease, a variety 
of metabolic or toxic encephalopathies, Gerstmann-Straussler 
syndrome, Schilder's disease, and striatonigral degeneration 
(18,20). 
Various subtypes of CJD have been described including 
"ataxic" (15,21,22) and "amyotrophic" (23) forms. In the 
ataxic form, cerebellar involvement represents the major patho-
logical and clinical findings. In this subgroup of CJD, cerebellar 
biopsy has been advocated as the best diagnostic procedure (15). 
Salazar et al (23) studied the so-called amyotrophic forms of 
CJD, which lack the spongiform changes of typical CJD and 
affect primarily lower motor neurons of the spinal cord, brain 
stem, and substantia nigra. They found them not to be trans-
missible, which was conoborated by Masters et al (24), Salazar 
et al (23) concluded that many such syndromes of dementia and 
early lower motor neuron signs are clinically and pathologically 
different from CJD, Dividing CJD into ataxic and amyotrophic 
forms may thus be enoneous. 
In view ofthe similarities of Alzheimer's disease to CJD, 
many authors have sought a commonality between the two dis-
eases (4,24-27). Both diseases are presenile dementias with 
equal sex preponderance. Age at onset and familial tendencies 
are common to both diseases, although the duration of 
Alzheimer's disease is much longer than that of CJD (eight years 
versus eight months). Brown et al (27) reviewed the clinical, 
pathologic, genetic, and biologic similarities between these two 
diseases, which are numerous (27). However, consistent trans-
mission of Alzheimer's disease to animals, considered to be of 
diagnostic significance in CJD, is not yet possible (27). Al-
though Tateishi et al (28) found similar staining characteris-
tics between Alzheimer's disease plaques and CJD amyloid, 
Pmsiner (29) has found immunohistochemical evidence to sug-
gest that the amyloid-type plaques of Alzheimer's disease are 
different from those of other transmissible dementias. Based on 
these observations, Alzheimer's disease and CJD don't appear 
to have comon etiologies (ie, prion or slow viral); however, 
search for a possible link between the two diseases continues, 
Pmsiner (30) suggests looking for clues to link slow, unconven-
tional viral diseases, or prion-induced diseases, to a number 
of neurological diseases including Parkinson's disease, 
amyotrophic lateral sclerosis, and Huntington's disease, as 
well as diabetes mellitus, rheumatoid arthritis, and lupus 
erythematosus. 
Etiology 
Subsequent to the first description of CJD, numerous world-
wide reports substantiated its sporadic distribution (31). Early 
attempts to identify its etiology were unsuccessful, although 
several hypotheses were suggested. In 1936 Josephy (32) impli-
cated a vitamin deficiency state similar to pellagra, due to eariy 
reported cases exhibiting features of dermatitis and diarrhea. 
Zimmerman (33) in 1928 and then Foley and Brown (34) in 1957 
suggested that the neuronal changes seen in CJD were second-
ary to a primary astrocytic disturbance. In 1960 Nevin et al (35) 
felt that "some form of vascular dysfunction without gross 
stmctural changes in blood vessels" was responsible for the dis-
ease, as evidenced by the gross postmortem similarities between 
CJD brain tissue and chronic anoxic encephalopathic brain 
tissue. In 1962 Siedler and Malamud (5) suggested that an en-
dogenously determined metabolic or biochemical defect may be 
the cause of, or at least contribute to, the degeneration. In sup-
port ofthis idea was Korey et al (36), who found areas of gener-
alized lipid depletion, especially in ganglioside fractions, in 
formalin-fixed, CJD brains. 
In 1962 Pany (37) published a review on scrapie, concluding 
that this disease was infective but that susceptibility to infection 
was genetically passed in an autosomal recessive pattern. He 
also felt that scrapie resulted via a dual mechanism of gene and 
provims, which was gene determined but which lacked certain 
properties of a natural virus. Pany seems to have predicted the 
nature of scrapie in an extraordinarily accurate manner. His 
ideas appear, at least in light of cunent evidence, to best explain 
evolving data. Each of the other, aforementioned hypotheses has 
been shown to be partially or totally inconect, although many 
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components of these early ideas may still fit the framework of 
cunent thought. 
The definitive work on the subject of CJD etiology was pub-
lished in 1968 (39), Two years after Gajdusek et al (38) showed 
that kuru, another unconventional, slow disease, was trans-
missible to chimpanzees, Gibbs et al (39) revealed that CJD was 
also transmissible to chimpanzees. Subsequently, Manuelidis et 
al (40-43) successfully passed human CJD to guinea pigs, ham-
sters, and mice, thus providing a good laboratory animal model 
for studying CJD. The demonstration of a transmissible demen-
tia has opened new avenues in neurological research. In fact, the 
concept of transmissible dementia has had such an impact on our 
understanding of neurologic disease that Gajdusek was awarded 
the Nobel Prize for his work with kum. 
Some authors have identified spiroplasma, a helical, motile 
mycoplasma, in CJD brain biopsies (44-46). Since this organ-
ism is often closely associated with vims particles. Gray et al 
(45) postulated that the CJD infectious particle may represent 
fragments of spiroplasma. However, Leach and Matthews (47) 
failed to detect this organism by cultivation and serological test-
ing in CJD brain tissue, nor could Manuelidis (4) detect the 
organism by electron microscopy. 
The aforementioned data argue for an infectious nature of 
CJD, and much work is cunently ongoing to identify the infec-
tious particle. However, by no means is the etiology firmly 
established as infectious. In 1983 Traub (10) put forth a 
provocative hypothesis that CJD may arise de novo by DNA mu-
tation. A unique view of the accumulated data on CJD supports 
Traub's ideas, which, as our knowledge of oncogenes and viral-
induced changes in nucleic acid expands, may prove to be com-
patible with the more widely held view that CJD is slow viral or 
prion induced (10). 
Despite advances in the understanding of CJD in recent years, 
its etiology remains only partially understood. As is usually tme 
with sound scientific experimentation, research in this area 
raises more questions than it answers. Our expanding under-
standing of scrapie and CJD has prompted us to reexamine the 
boundaries that separate the so-called genetically passed dis-
eases from infectious diseases. 
Biochemistry 
Injection of certain protein-enriched fractions isolated from 
CJD-infected brains into the brains of nonnal animals results in 
CJD infection in the animal. Thus, contained in the fraction is 
all the information needed for infection. The mechanism by 
which these protein fractions interact with the uninfected host to 
produce disease remains unknown. In addition, other problems 
obscure our understanding of this agent: 1) it has not been un-
equivocally visualized by electron microscopy, 2) a nucleic acid 
content or other macromolecular stmctural components have not 
been completely identified, and 3) the particle does not elicit a 
humoral or cell-mediated immune response (48). 
While the etiology of CJD is generally thought to involve 
some sort of infectious particle, characterization of that particle 
has been fraught with difficulty. Much of our cunent under-
standing of CJD and CJD-related agents is extrapolated from 
data utilizing the more easily studied scrapie agent. In a land-
mark article in Science, Pmsiner (30) reviewed some ofthe bio-
chemical properties of the scrapie agent, coining the term 
"prion," which stands for proteinaceous infectious (particle). 
The agent is ineversibly inactivated by alkali, which denatures 
RNA, double-stranded DNA, and protein, but is resistant to nu-
clease digestion, ultraviolet inadiation, incubation with zinc, 
photochemical inactivation with psoralens, and inactivation 
with hydroxylamine (30). As these procedures tend to degrade 
nucleic acid but not affect the agent, either the CJD agent con-
tains no nucleic acid or its nucleic acid is well protected (30). 
The agent, however, is sensitive to protease inactivation, indicat-
ing a necessary protein component (30). The agent is hydro-
phobic and occurs in various sizes, the smallest with a molecular 
weight under 50,000, which is too small to contain enough nu-
cleic acid to code for an infectious protein. Numerous hypoth-
eses have arisen concerning the nature of the scrapie agent, 
including self-replicating proteins, polysaccharides, or 
nucleoproteins; membrane bound DNA; viroids; and virinos 
(30,48). 
One month after Pmsiner described prions in 1982, Kimberlin 
(49) proposed that the agent be classified more appropriately as 
a virino. Virinos lie somewhere between viroids and vimses bio-
logically. Viroids are infectious particles of plants composed of 
single-stranded, closed, circular RNA, are devoid of protein, 
and replicate but are not translated. Considerable controversy 
exists over how to classify the scrapie-causing agent. The fol-
lowing five working hypotheses were set forth by Pmsiner (30): 
If the agent does indeed contain "protected" nucleic acid, it may 
1) code for the prion protein, or 2) activate transcription of host 
genes coding for prion proteins. Altematively, if the agent is de-
void of nucleic acid, its protein may 3) activate transcription of 
host genes coding for prion protein, or code for its own replica-
tion by either 4) reverse translation or 5) protein directed protein 
synthesis (30). These hypotheses must be considered in light of 
cunent ideas about molecular biology and genetics wherein 
DNA is transcribed to RNA and then translated to protein. Re-
verse translation has not yet been described in biology, and is, as 
has been described by many, "clear biological heresy." Johnson 
(48) concisely reviewed the cunent ideas conceming the scrapie 
agent, addressing the work of both Pmsiner and Kimberlin. He 
elegantly captures the excitement inherent in this area of slow 
viral research in his closing lines, referring to Pmsiner's prions: 
"If they are regulatory proteins that activate the host genes to 
synthesize themselves, they will rattle the shutters of biology; if 
they are proteins capable of reverse translation or protein-di-
rected synthesis, they will shake the foundations" (47). 
Are the "shutters" starting to rattie? In 1983 McKinley et al 
(50) isolated a unique protein, PrP 27-30, shown to be a major 
component of the infectious scrapie particle in hamsters and 
capable of polymerizing into amyloid-type rods (51). Bendheim 
et al (52) succeeded in producing antisemm to PrP 27-30 and 
recently described cross-reaction of this antisemm with parti-
cles causing CJD in rodents (53). In 1985 Bockman et al (54) 
provided evidence for prion proteins in human brains infected 
with CJD; these prion proteins cross-react with the PrP 27-30 
antiserum from hamsters and are histochemically similar 
to amyloid, ie, stain with Congo red and exhibit green 
birefringence under polarized light. Thus, antiserum to PrP 
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27-30 may be used to locate CJD prion proteins in brain tissue 
and may well supplant the transmissibility criterion as discussed 
previously. 
Merz et al (55,56) have identified similar low molecular 
weight protein isolated from synaptosomal preparations of 
scrapie-infected hamster brain, as well as human CJD-infected 
brain. They call this protein scrapie-associated fibrils (SAF), 
which may represent either 1) a unique pathological response to 
the disease, or 2) the infectious agent itself (55,56). Diringer et 
al (57) further purified the SAF and conoborated the work of 
Merz et al. This protein seems analogous to the prion protein 
described by Pmsiner, not only in biochemical properties and 
distribution but also when examined by electron microscopy, 
and has in fact been found to be composed of protease resistant 
glycoprotein (58). 
Brain monoamine abnormalities have been found in both the 
"amyotrophic" and "typical" forms of CJD (59). These abnor-
malities consist of reduced dopamine concentration in the cau-
date nucleus, putamen, and mesencephalon in the amyotrophic 
form, and reduced dopamine in the putamen only in the typical 
form (59,60). This information is of interest in light of the bene-
ficial therapeutic effect of amantadine reported in several cases 
of CJD (61,62). In addition to its antiviral actions, amantadine 
increases brain dopamine levels, probably by releasing endoge-
nous dopamine. Some reduction in brain norepinephrine con-
centration has been seen in both forms, but not to the same 
degree as dopamine (59). Little change in brain serotonin con-
centration has been noted in either form (59). 
Timperly et al (63) demonstrated a loss of oxidative and 
lysosomal enzymes in neurons in one case of CJD, These work-
ers also found loss of cytoplasmic RNA and nuclear DNA, as 
well as accumulation of lipofuscin in neurons of the same case 
(63). The significance of these latter findings is unknown, but 
the former may help explain the lack of immunological or 
inflammatory response common in CJD. 
Neuropathology 
Transmissibility of the degenerative changes constitutes the 
definitive diagnostic criterion used in classifying CJD. Spongy 
changes usually in the neuropil (due to progressive fusion of 
swollen cellular processes) but occasionally in neurons and as-
trocytes, along with variable degeneration of neurons and astro-
cytic gliosis (both hypertrophic and hyperplastic), represent the 
major pathological alterations of affected brain regions (64-67), 
These changes gave rise to the term subacute spongiform en-
cephalopathy. In addition, amyloid plaques have been a variable 
finding in CJD, which is of interest considering the work of 
Pmsiner et al (30,51). Masters and Richardson (64) distinguish 
between the terms spongiform change and status spongiosum, 
the latter designating nonspecific, end-stage gliosis typified by 
inegular cavitation of the neuropil accompanied by a dense glial 
meshwork. Conversely, spongiform change designates small, 
round, or ovoid vacuoles within the neuropil, the result of a 
more acute process (64). In their review of 24 cases of CJD 
in humans. Masters and Richardson (64) found the cerebral 
cortex to be most severely involved, as judged by the degree of 
neuronal loss, gliosis, and spongiform change, followed by the 
dorsomedial nucleus of the thalamus, caudate, putamen, and 
cerebellum. The anterior nuclear thalamic groups and ventral 
lateral thalamic nucleus were affected to a lesser extent, while 
the hippocampus, midbrain, pons, medulla, and spinal cord 
were minimally affected (64). 
Manuelidis, in his 1985 Presidential Address to the American 
Association of Neuropathologists, nicely reviewed the neu-
ropathologic changes seen in this disease, particularly with 
respect to transmissibility to animal models, which has both di-
agnostic and research significance (4). 
Arendt et al (68,69) demonstrated neuronal loss in the basal 
nucleus of Meynert (a major cortical cholinergic projection cen-
ter), which may help explain the dementia and cholinergic defi-
ciency often seen in this disease. These authors found identical 
pathology in the brains of patients with Alzheimer's disease 
(68). Hauw et al (70), who reviewed 50 cases of CJD with cere-
bellar involvement, found no conelation between the presence 
of clinical cerebellar signs and symptoms and prominent cere-
bellar changes pathologically. They concluded that a cerebellar 
variant of CJD is not likely, in contrast to views held by other 
authors which suggest a special cerebellar subgroup (70,71). 
Meier (72) demonstrated isolated, small, dark cells near in-
volved neurons and astrocytes, which he thought were most 
likely lymphocytes. He concluded that transmission of CJD may 
be mediated by blood cells bearing the infectious particle (72). 
Supporting this idea is the observation that viremia in experi-
mental CJD-infected guinea pigs occurs following leukocyte 
inoculation (73,74). 
The gray matter changes discussed represent the relevant 
pathology in most cases of CJD, However, adherence to strict 
criteria of spongiform change and neuronal destmction in diag-
nosis of CJD may be misleading. The disease can be present 
without spongiform change and may involve extensive white 
matter degeneration (75). In a study of retinal degeneration of 
CJD-infected mice, Hogan et al (76) found pathological sim-
ilarities between human retinal diseases, such as retinitis pig-
mentosum, retinitis punctata albicans, and senile macular 
degeneration, and their mouse model. These authors speculate 
as to possible slow viral etiologies of so-called "genetic" dis-
eases. Roth et al (77) found vims-like particles in the optic nerve 
head of a patient with CJD, which were morphologically similar 
to those found in the brain. This finding supports the suggestion 
of a slow viral etiology for some retinal degenerations in man. 
For extensive descriptions of light microscopic as well as 
scanning and transmission electron microscopic findings in the 
CJD-infected brain, interested readers are refened to the works 
of Chou et al (78), Kim and Manuelidis (66), or Manuelidis and 
Manuelidis (79). Chou et al (78) found no evidence of conven-
tional viral stmctures in affected tissues examined by both trans-
mission and scanning electron microscopy. They found only 
membrane alterations and particulate structures on intravacuolar 
membranes (78). Bockman et al (54) published electron micro-
graphs of prion amyloid-type rods, although amyloid deposition 
is not a consistent finding in CJD, occurring in about only 12% 
of all cases. 
CJD-causing agents, whatever their constitution, represent a 
hazard to neuropathologists working with diseased tissue, be-
cause of their unusual resistance to aldehyde fixatives (80-82). 
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Infectivity is reported to be maintained even in paraffin-embed-
ded tissue blocks (83). Brown, Baringer, and others (80-84) rec-
ommend autoclaving tissue for one hour at a temperature of at 
least I2 rc (15 psi) as the procedure of choice for CJD inacti-
vation; however, a one-hour exposure to 0.5% sodium hypo-
chlorite is a good alternative. Masters et al (85) reported a 
procedure for decontaminating formaldehyde fixed tissues by 
autoclave, without loss of microscopic visual quality. However, 
this latter procedure does destroy immunoreactivity (85). 
Epidemiology 
According to Masters et al (31), distribution of CJD is world-
wide, having been reported on five continents. Possible cluster-
ing of cases has been reported in England, Czechoslovakia, 
Hungary, and among Libyan Jews (9,31). No urban-rural 
differences have been reported, and estimates of the annual inci-
dence of CJD per 1 miflion range from 0.1 to 5, with 1 per 1 mil-
lion accepted by many authors to be a reasonable estimate 
(4,9,31,86). This figure also represents the prevalence rate, 
because the average duration of disease is about one year (9,30). 
The range of age at onset is reported to be between 35 and 65, 
with a mean age of mid 50s reported by various authors (9,32). 
However, patients as young as 20 years old have been described 
with spontaneous CJD (87), While it is hard to ascertain the ex-
act date of onset in CJD, the mean duration of disease is consid-
ered to be eight to 12 months, although cases of up to 13-years 
duration have been reported (9), The male to female ratio of CJD 
is close to one (9), 
The Libyan Jewish population in Israel represents the only 
obvious racial bias in CJD occunence, with a cmde rate of 51 per 
1 million annually (9,88), This bias may reflect genetic suscep-
tibility or increased exposure to an unknown risk factor (88), 
Curiously, the practice of eating animal brains and sheep eyes is 
popular among this population group (88). 
The mode of transmission of CJD is still uncertain. Ongoing 
research is working to substantiate an infectious etiology, and 
transmission is thought to occur by one of three general mecha-
nisms: 1) iatrogenic exposure, 2) occupational exposure to CJD 
patients or animals, or 3) preparation or consumption of CJD-
infected brain tissue or raw meat (9). 
Iatrogenic causes have been confirmed in an increasing 
number of CJD cases. Two patients contracted the disease fol-
lowing contact with intracerebral EEG electrodes contaminated 
by a CJD patient (89), and one patient contracted the disease fol-
lowing a corneal transplant from a CJD-infected donor (90). 
Nevin et al (35) found that four of eight CJD patients studied had 
a history of intracranial surgery or ventriculography 16 to 24 
months before onset of the disease. In a study of 60 cases of 
CJD, Kondo and Kuroiwa (91) concluded that physical injuries 
and operations may be a predisposing factor to the development 
of the disease. However, in a case control study of 38 patients, 
Bobowick et al (92) found no significant difference between 
groups of patients with prior cranial or surgical histories and the 
controls. Similarly, Matthews (93) reported that only two of 46 
patients had a prior history of intracranial surgery. Koch et al 
(94) and Gibbs et al (95) described iatrogenically-induced CJD 
in young patients receiving human cadaveric growth hormone. 
Brown et al (96) commented on the "ominous possibility of a 
burgeoning epidemic" of CJD due to use of human growth 
hormone. 
The familial form of CJD that exists is estimated to represent 
12% to 14% of all cases. It is inherited in an apparently auto-
somal dominant manner (9,26). A female predilection is evi-
dent, but matemal and patemal lines are affected equally (26). In 
a study of 37 families with the familial form of CJD, Masters et 
al (26) found no direct evidence to support prenatal vertical 
transmission; however, affected siblings tended to die at similar 
ages, though not at the same time, which suggests vertical trans-
mission. Despite the latter findings, they concluded that a genet-
ically inherited susceptibility to infection, acquired early in life, 
is most probable in CJD (26). 
IVeatment 
Although current research activity with the scrapie agent 
points away from a viral etiology, many still classify the CJD 
agent as viral. Antiviral dmgs such as amantadine, acyclovir, 
vidarabine, and interferon, and even various antibacterial dmgs 
have thus been tried in the treatment of CJD, but with little 
success. Acyclovir, a DNA vims inhibitor, was found to be inef-
fective in both early and late stages of the disease (97,98). Inter-
feron has been reported to be useful in treating experimental 
scrapie (99), but use in humans with CJD has proven disappoint-
ing. However, it may fail to reach sufficient concentration in 
cerebrospinal fiuid, being only 'Ao of serum concentrations 
(100). Thus, the efficacy of intrathecal interferon administration 
should be assessed. Thiamphenicol, rifampicin, cytosine arab-
inoside, and isoprinosine have been tried in experimental CJD in 
mice, without significant effect (101). Vidarabine suppressed 
some motor symptoms in one reported case of CJD, but failed to 
halt progression of the disease (102). Amantadine is the only 
agent reported to have significant therapeutic effects, but only in 
isolated cases (103,104). Terzano et al (103) reported a transient 
improvement in wakefulness and mentation, and reduction in 
EEG slow-wave activity and periodic discharges with aman-
tadine therapy. Braham (105) felt these effects may correlate 
with amantadine's ability to increase central dopamine, a bio-
chemical rather than antiviral effect. This information makes 
sense in view of the work of Nyberg et al (58), who showed a 
consistent reduction in brain dopamine concentration in CJD-
infected human brain. Braham (105) tried 5 g/day of levodopa 
via a nasogastric tube in one CJD patient without improvement, 
although this patient's brain may have been sufficiently damaged 
to render it unable to convert levodopa to dopamine. In view of 
this, it may be worthwhile to try other dopaminergic dmgs such 
as bromocriptine or pergolide mesylate as Braham suggests 
(105). Roikhel et al (106) tried the monoamine oxidase inhibitor 
aminasine in a mouse model of scrapie and found no effect when 
administered intraperitoneally. These workers did, however, 
find a prolonged incubation period and slight decreased mor-
bidity when aminasine was injected intracerebrally (106). Kudo 
et al (107) reported the disappearance of sleep apnea, and peri-
odic synchronous discharges on EEG, by tracheal intubation, 
suggesting that both manifestations of CJD could be due to air-
way obstmction. 
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In short, there remains no consistently efficacious therapy in 
the treatment of CJD, save supportive measures. However, con-
tinued advances in our understanding of the etiology of CJD and 
the biochemical nature of the disease process will, in the future, 
reveal specific areas where pharmacological manipulation may 
improve the lives of patients with this disease and related 
afflictions. 
Conclusion 
A word about naming the scrapie agent is in order due to the 
heated debates over the nature of its replicative machinery. Al-
though Pmsiner has prolifically saturated the literature with the 
term prion, which by virtue of its constmction emphasizes pro-
tein, all researchers are not of similar persuasion. Kimberlin, a 
strong opponent of the self-replicative protein hypothesis, holds 
that the particle is "vims-like." Work by Rohwer (108) serves to 
substantiate the validity of Kimberlin's claim. Recent ultraviolet 
inactivation data suggest that the particle could be a small vims, 
although it is clear that its putative nucleic acid is "atypical," 
possibly bound to another macromolecular stmcture, ie, protein 
or cell membrane (108,109). In addition, the sedimentation 
behavior and buoyant density in centrifugation experiments sup-
port a nucleic acid component (108). Exclusion size in perme-
ation chromatography is also in support of this contention (108), 
as is recent data by German (110) who found a population of 
small RNA molecules present only in scrapie-infected mice. 
Kimberlin (111) points out that genetically stable, biologically 
different strains of the scrapie disease exist, which strongly im-
plicates the necessity of a highly efficient, precise method of 
replication, deemed possible, he thinks, only with nucleic acid 
(112), A recent suggestion by Hope and Kimberlin (58) is that 
the infectious agent may become protected by a host-coded pro-
tein resulting in infectivity. 
In support of Pmsiner (29), he does not claim that prions are 
by definition devoid of nucleic acid. He upholds only that pro-
tein is necessary for infection (29). Pmsiner and coworkers (113) 
have partially sequenced the PrP 27-30 protein, and Oesch et al 
(114) have found evidence for a cellular gene which encodes this 
protein, both in normal and infected tissue. These data argue for 
scrapie or prion specific nucleic acid, but whether the nucleic 
acid containing this information is contained in the infectious 
particle itself or simply canied in host genes is controversial and 
the subject of cunent research. 
1 uphold the views of Johnson (48), in that a conservative ap-
proach be applied to naming the agent. Until its macromolecular 
stmcture is conclusively revealed, definitive classification of the 
agent should be withheld. Whatever its constitution, one point is 
clear: the understanding of scrapie and CJD has brought us to 
new frontiers in molecular biological research and has added 
greatly to our understanding of central nervous system disease. 
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